A rape was reported to the University’s deputy Title IX coordinator, according to Thursday’s Notre Dame Security Police (NDSP) crime log.The alleged rape occurred in a men’s residence hall between the night of Aug. 31 and the morning of Sept. 1.Information about sexual assault prevention and resources for survivors of sexual assault are available online from NDSP and from the Title IX office.Tags: NDSP, NDSP crime log, sexual assalt, Title IX
Florstien was preceded in death by her parents and is survived by two grandsons Ronnie Romero and Randy Romero and one sister, Juanita McKinney of Ratliff, Texas. Visitation will be on Tuesday, December 18, 2012 from 5:00 P.M. until 8:00 P.M. at Clayton Thompson Funeral Home. Funeral Service will be held Wednesday, December 19, 2012 in the Thompson Chapel of Clayton Thompson at 10 A.M. with internment to follow at Greenlawn Memorial Park. Florstien Romero, 95 of Port Neches passed away on Saturday, December 15, 2012 at The Medical Center of Southeast Texas. She was born on November 12, 1917 in New Iberia, Louisiana to Etinne and Eva Viator Landry. Florstien was a member of St. Charles Catholic Church and was active in the Altar Society.
Next Up He is survived by two daughters, Kimberley Kleypas, and Desiree Montie, a grandchild Christian Beavers, his mother Shirley Kleypas, brothers and sisters Kay Mason, Ricky and Theresa Kleypas, Yvonne Kleypas, Joanie Kleypas, Lori and Patrick Plott, and Michael and Jynatha Kleypas. Kenny is best remembered for his big smile, his artistic ability and craftsmanship, his love of the Gulf, but mainly for his generosity and compassion for friends and animals. In lieu of flowers, please make a donation to the Animal Shelter of Southeast Texas, 2050 Spindletop Ave., Beaumont, TX 77705 Details and online guest registry available at Melancons.org. Memorial Service will be held on Monday, November 7, 2011, from 5:00 p.m. to 7:00 p.m. at Melancon’s Funeral Home, 1605 Avenue H, Nederland, TX. Kenneth Ray Kleypas (“Kenny”), 62 of Port Acres, passed away on Friday, November 4, 2011 after accidentally slipping and drowning near his boat in Port Acres, TX. Kenny was born in Temple, TX on August 18, 1948, the first of seven children of A.C. (“Dick”) and Shirley Kleypas. He graduated from Bishop Byrne High School in 1967 and attended Lamar University. His high school motto was “He’ll do anything once, sometimes twice” which so colorfully described his free-spirit philosophy. He served in the U.S. National Guard (Company C) between 1969 and 1975, and worked at the Mobile Oil Refinery in Port Neches, TX. Kenny lived his passion for boats and fishing. He lived on his 48 ft Hatteras yacht, the “Fish Tales” in Port Acres for the last ten years. He was a certified boat captain, and once won the SALT fishing Tournament. He twice weathered his vessel through major storms, Hurricanes Rita and Ike, and enjoyed many fishing adventures prior to that. He was a meticulous craftsman, but he was also a great cook and storyteller. He generously shared many stories and a lot of his seafood with his friends and family.
I don’t like watching other cyclists crash but this video, this one held me transfixed. Apparently, racing elbow to elbow in a peleton (especially in a Cat 4) can be just as dangerous as racing downhill bikes.According to the YouTube poster, the first rider to crash was up and walking after the incident, but was taken to the hospital afterwards just in case.
Come From Away The exciting new musical Come From Away surprised audiences when it opened on Broadway in March. The moving true story of generosity at a time of worldwide trauma was something not often portrayed onstage. Featuring an original score by Broadway newcomers Irene Sankoff and David Hein and directed by 2017 Tony winner Christopher Ashley, Come From Away has become a bonafide Broadway success. The cast of supertalents took to the stage of Good Morning America on August 23 to give TV viewers a sample of the story they are telling eight times a week. Watch Tony nominee Jenn Colella and her fellow cast perform the lively number “Screech In” to Kelly Devine’s Tony-nommed choreography, and make your way to the Schoenfeld Theatre to experience Come From Away firsthand. from $49.00 Related Shows View Comments
The Skechers GO RUN Razor 3 Hyper performance training shoe has taken the Runner’s World top honour – having been awarded ‘Gear of the Year’ in its September/October 2019 issue. Featuring the Skechers-developed Hyper Burst midsole foam, the shoe was previously named ‘Editors’ Choice’ in a Runner’s World cover story earlier this year.Products that earn the ‘Gear of the Year’ award are selected from the past year’s ‘Editors’ Choice’ winners. These products rank at the top not only via on-the-road testing, but also in measurements at the magazine’s shoe lab, as well as in delivering excellent value for the runner.Runner’s World editors singled out the Skechers GO RUN Razor 3 Hyper due to its new midsole and performance that ranked highly among wear-testers. It also stood out by offering responsive cushioning that felt protective for such a lightweight shoe.“It’s been an incredible year for our Hyper Burst performance running shoes,” said Michael Greenberg, president of Skechers. “Runner’s World naming the Skechers GO RUN Razor 3 Hyper an ‘Editors’ Choice’ in the spring marked a new era for our Performance Division, but to be back in the magazine as best of the best on the ‘Gear of the Year’ list is a true honour.“Our team of designers introduced a ground-breaking evolution with Hyper Burst, which is now found in a range of styles throughout our collection. This recognition serves as a reminder that every type of runner can turn to Skechers for shoes that are lightweight, while still offering the comfort and support they desire.”Introduced by the Skechers Performance Division in November 2018, the foundation of the 6.4 oz. Skechers GO RUN Razor 3 Hyper is the Hyper Burst midsole. This is made using a ‘super critical’ foaming process to create spherically-shaped cells in a tight format. It is billed as ‘the lightest and most resilient midsole foam that Skechers Performance has offered to date.’ Skechers adds that the unique irregular cell structure is unlike most other EVA foams on the market today.The style also features a durable, translucent engineered monomesh upper that helps to ensure support and breathability, plus strategically-placed rubber on the outsole for durability and traction. A seamless upper construction helps enhance comfort, while the signature M-Strike technology helps promote a midfoot strike for greater efficiency in every stride.Styles featuring Hyper Burst have been consistently earning awards this year. Outside named Skechers GO RUN 7 Hyper ‘Gear of the Year’ for the road running category in its Summer 2019 Buyer’s Guide. Skechers also made an impression at the Outdoor Retailer 2019 show with its upcoming road running shoe – Skechers GO RUN Maxroad 4 Hyper – earning two editorial awards, ‘Best of Outdoor Retailer’ award by Shape magazine, as well as ‘Editors’ Choice Outdoor Retailer’ by Runner’s World.www.skechers.com Related
The ECDC’s action in dropping the name without an explanation was sharply criticized by Michael T. Osterholm, PhD, MPH, director of the University of Minnesota’s Center for Infectious Disease Research and Policy, publisher of CIDRAP News. The original report published Jun 29 stated that AGA SAAT GMBH of Dusseldorf, Germany, supplied seeds to a British firm (previously identified as Thompson & Morgan) that sold the seeds used to grow the sprouts linked to the E coli cases in Bordeaux, France. The company was named in a Jun 29 CIDRAP News story based on the report, which was published by the ECDC and the European Food Safety Authority. Also today, CIDRAP News received an e-mail message from a German attorney who said that he represented AGA SAAT GMBH and demanded that the firm’s name be removed from our Jun 29 news story based on the ECDC report. The message threatened legal action if the name is not removed. “We hope that this helps to clarify why the name of the company is not included anymore.” An examination by CIDRAP staff members of online documents indicated that the original ECDC report was replaced by a revised version about 9 hours after it was published on Jun 29. Most of the currently available media stories about the report do not mention the firm’s name, but at least one Reuters report, in the French newspaper Le Figaro, still mentioned it today. But the name of the German firm was removed from the online ECDC report a few hours after it was first published, CIDRAP News has learned. The current version of the report omits the name without giving any explanation for the change. “Nevertheless, alreadyby itselfthe nomination of the name of our client in connection with possibly EHEC contaminated seed is suitable for damaging her reputation. Therefore, we request you to delete immediately the name of our client from your above article. Jul 1, 2011 (CIDRAP News) The European Centre for Disease Prevention and Control has deleted the name of a German seed importer from a risk assessment report on the recent cluster of Escherichia coli cases in France, out of concern about potential unnecessary harm to the company, CIDRAP News learned today. The message from Dr. Philipp Giesen of the firm Rellermeyer Partner in Dusseldorf states, “In your article on your website [link included] our client is wrongly brought in connection with the supply of possibly EHEC contaminated seed. So far, in the context of intensive inspections neither in the case of supplies to our client nor in the case of supplies of our client EHEC exciters were determined. “We look forward to the confirmation of the deletion until the 2nd of July 2011. The report said fenugreek seeds imported from Egypt in 2009 and/or 2010 were implicated in the French illness cluster. The E coli strain in the French illnesses matches the strain in the massive E coli outbreak centered in Germany. The ECDC and EFSA called for urgent investigations into the distribution of the implicated lots of seeds, because of a risk of more cases. In response to a query today about the reason for removing the company’s name, ECDC spokeswoman Caroline Daamen told CIDRAP News by e-mail, “In the initial risk assessment posted on the website, EFSA and ECDC reported information that had been made available to support the ongoing outbreak investigation. However, some key partners involved felt that it may unnecessarily harm the company to publish its name while the investigations are still ongoing. So it was thought more appropriate to remove the name of the company from the final report. See also: Original Jun 29 ECDC report Revised ECDC report “We also reserve our right to take further legal measures against you.” “I really think they compromised public health practice by removing the name of the company and not saying why, particularly since more fenugreek seeds may still be out in the public domain,” he said. “If it [the naming of AGA SAAT GMBH] is not correct, they should go back and correct that,” he added. “But if they’re letting the company dictate to them, they’re really not doing their job. It really is public health malpractice not to name these companies when they’re involved, particularly when there’s a potential risk to the public as a result of their product still being on the market.” Jun 29 CIDRAP News story on ECDC report
Researchers in the United Kingdom report that a frontline drug combination for the treatment of uncomplicated malaria failed in four patients, a finding they say raises concerns about reduced susceptibility to recommended therapy for the disease.Meanwhile, a separate study suggests that a gene that enables malaria-carrying mosquitoes to resist insecticides has spread throughout southern Africa.The case studies, reported this week in Antimicrobial Agents and Chemotherapy, describe the treatment of four patients (two male, two female) diagnosed as having malaria caused by the Plasmodium falciparum parasite after returning from trips to Angola, Liberia, and Uganda in late 2015 and early 2016. Most malaria cases in the UK involve people who’ve traveled to Africa, where the disease is endemic.The patients were all treated with artemether-lufemantrine, an artemisinin-based combination therapy (ACT) that the World Health Organization (WHO) recommends as the first-line treatment for uncomplicated malaria. All the patients recovered within a few days, and were discharged once their blood showed no remaining signs of the parasite.Treatment failureBut from 2 and 6 weeks after the initial episode, each patient returned with recurrent symptoms of the disease and increased levels of the parasite in their blood. None of the four patients had traveled back to Africa after the first treatment, which indicated that these were not new infections, since P falciparum is not found in the United Kingdom. Doctors subsequently treated the patients with alternative drugs, and all four recovered.Genetic analysis of malaria isolates from each patient showed that they all harbored mutations that have been associated with reduced susceptibility to artemisinin or lufemantrine. Still, the authors note, the failure of the initial treatment “cannot be unequivocally ascribed to parasite resistance” in the four patients. They say the findings could have been substantiated by monitoring the patients for full compliance with the initial treatment and measuring lufemantrine levels in the blood a week after treatment to look for signs of malabsorption.While the four cases represent the first failure of frontline malaria treatment in the United Kingdom, the authors of the study say the real concern is what the findings could potentially mean for malaria treatment in Africa, where the parasite is a constant threat and artemeter-lufemantrine is the most widely used ACT.Lead study author Colin Sutherland, PhD, MPH, of the London School of Hygiene and Tropical Medicine, said UK doctors can play a role in monitoring for signs of growing resistance.”A concerted effort to monitor AL [artemether-lufemantribe] outcomes in UK malaria patients needs to be made,” Sutherland said in a press release from University College London Hospitals. “This will determine whether our frontline drug is under threat.”As of July 2016, resistance to artemisinin and its partner drugs has been confirmed in the five countries that make up the Greater Mekong subregion: Cambodia, Laos, Myanmar, Thailand, and Vietnam.Insecticide resistance in AfricaWhile resistance to artemisinin-based combination therapies has not to date spread to Africa, a study today in PLoS Genetics indicates that one of the major elements of malaria control efforts in Africa is helping fuel the spread of insecticide-resistance in the mosquitoes that carry P falciparum.According to the study, a vast majority of malaria reduction since 2000 can be attributed to mosquito control with pyrethroid insecticide-based interventions, including the use of insecticide-treated bed netting and indoor spraying. Yet in recent years, growing resistance to insecticide-treated nets has been observed in Africa. That resistance is believed to be caused by a metabolic mutation that enables mosquitoes to detoxify the insecticide before it reaches its target.To get a better understanding of why this resistance is spreading, and how far it has spread in mosquito populations in Africa, researchers used a combination of sequencing techniques and genetic analyses to examine the continent-wide population structure of the Anopheles funestus mosquito, one of the major malaria vectors in Africa. What they found was that the gene that controls metabolic resistance has now swept through mosquito populations in southern Africa and become almost universal, driven primarily by the selection pressure from the growing use of pyrethroid-treated mosquito netting.”This highlights the risk of relying on a single insecticide class for vector control and emphasizes the need for novel insecticides and vector control tools to tackle the spread of resistant vector populations,” the authors write.The WHO estimates there were 212 million cases of malaria globally in 2015, and 429,000 deaths. Africa accounted for 90% of the cases and 92% of the deaths.See also:Jan 30 Antimicrob Agents Chemother studyJan 31 University College London Hospitals press releaseFeb 2 PLoS Genet study
Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270. Subscribe
Subscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.